Why NRx Pharmaceuticals Stock Vaulted Higher Today
Shares of NRx Pharmaceuticals (NASDAQ: NRXP) were vaulting 15.1% higher as of 3:25 p.m. EDT on Monday. The nice gain came after Israeli media reported that participants in a clinical study evaluating experimental COVID-19 vaccine BriLife maintained a high level of protection six months after a second dose and didn't need a third booster dose. NRx owns exclusive global rights to market the BriLife vaccine, which was developed by the Israel Institute for Biological Research.
NRx Pharmaceuticals has been one of the worst-performing vaccine stocks in 2021, with its shares sinking more than 50% as of the market close on Friday. It's not surprising that investors welcomed the news about the potentially long duration of protection for BriLife.
Image source: Getty Images.
Source Fool.com
